Other Sellers on Amazon
+ $16.62 shipping
100% positive over last 12 months
Download the free Kindle app and start reading Kindle books instantly on your smartphone, tablet, or computer - no Kindle device required. Learn more
Read instantly on your browser with Kindle for Web.
Using your mobile phone camera - scan the code below and download the Kindle app.
The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World Hardcover – July 26, 2022
| Price | New from | Used from |
|
Audible Audiobook, Unabridged
"Please retry" |
$0.00
| $7.95 with discounted Audible membership | |
|
Audio CD, MP3 Audio, Unabridged
"Please retry" | $27.29 | — |
- Kindle
$6.16 Read with Our Free App -
Audiobook
$0.00 Free with your 3-Month Audible trial - Hardcover
$6.4831 Used from $2.49 31 New from $6.48 - Audio CD
$41.992 New from $27.29
Purchase options and add-ons
The inside story of an unprecedented feat of science and business.
At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical.
Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama—a David to Big Pharma's Goliaths—turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same.
Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize–finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever.
The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.
- Print length320 pages
- LanguageEnglish
- PublisherHarvard Business Review Press
- Publication dateJuly 26, 2022
- Dimensions6.25 x 1.25 x 9.5 inches
- ISBN-101647823196
- ISBN-13978-1647823191
Frequently bought together

What do customers buy after viewing this item?
- Lowest Pricein this set of productsThis item:
The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the WorldHardcover$16.62 shipping - Most purchased | Highest ratedin this set of products
The Song of the Cell: An Exploration of Medicine and the New HumanHardcover$17.44 shipping
Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible PossibleDr. Albert BourlaHardcover$16.38 shipping
A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 VaccineHardcover$16.86 shippingGet it as soon as Monday, Jul 24Only 1 left in stock - order soon.
From the Publisher
|
|
|
|
|---|---|---|
|
|
|
|
Editorial Reviews
Review
"This book offers a fascinating view inside the company behind the vaccine." — CHOICE, the publication of the American Library Association
"Mr. Loftus' book is an easy and great read for anyone interested in science and business." — Business Standard
"Wall Street Journal reporter Peter Loftus provides the inside track on the company in The Messenger, an engagingly pacy yet detailed narrative that traces the scientific origins of the Moderna story through the various dramas that led to the licensing of the vaccine in December 2020." — The Irish Times
"Offers readers an inside view of the company's ascent from secretive startup to one of the most valuable health care companies in the world." — Science magazine
"Based on nearly 300 interviews with more than 150 people, including Moderna employees, co-founders, members of the company's board and investors past and present, the book tells the story of the bet Moderna made on developing a vaccine for Covid-19." — Financial Times
"Wall Street Journal reporter Loftus charts in his captivating debut Moderna's spectacular rise from a small biotech company with "no products [and] no profits" in 2018 to a key player in the race for a Covid-19 vaccine." — Publisher's Weekly
"A satisfying look at how a smart business can both identify opportunity and do well by doing good." — Kirkus Reviews
Advance Praise for The Messenger:
"The Messenger delivers a riveting account of Moderna's unprecedented quest to develop a vaccine against Covid-19. With deep reporting and clear writing, Loftus compellingly chronicles the high-stakes drama behind one of the most important science-business stories of our time." — Ron Winslow, former Deputy Bureau Chief, Health and Science, and award-winning medical reporter, the Wall Street Journal
"Peter Loftus's new book is an in-depth look at how a controversial startup whose vaccine was one of the few miracles of the pandemic rose from nothing to a company that at its peak was valued at over $200 billion. The book is part business story, part science story, and entirely a story of people who wouldn't entertain the notion of failure." — Bethany McLean, contributing editor, Vanity Fair; columnist, Thomson Reuters; and coauthor, New York Times bestselling author, All the Devils Are Here
"The Messenger is a compelling, page-turning story of the development of the mRNA vaccine for Covid-19 by a collaboration between Moderna and scientists at the National Institutes of Health. Given the incredible importance of mRNA vaccines in combating both Covid-19 and other pathogens in the future, this well-written, accessible, and exciting narrative is a must-read." — Monica Gandhi, MD, MPH; Professor of Medicine and Associate Division Chief, HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco
About the Author
Peter Loftus writes about the pharmaceutical industry and health care for the Wall Street Journal. Based in Philadelphia, he covers large drugmakers, biotech firms, and the latest developments in drug research and innovation. He has followed Moderna and the wider chase for a Covid-19 vaccine from their start. He is part of a Journal reporting team that was a finalist for the Pulitzer Prize.
Follow Peter Loftus on Twitter @loftus.
Product details
- Publisher : Harvard Business Review Press (July 26, 2022)
- Language : English
- Hardcover : 320 pages
- ISBN-10 : 1647823196
- ISBN-13 : 978-1647823191
- Item Weight : 1.2 pounds
- Dimensions : 6.25 x 1.25 x 9.5 inches
- Best Sellers Rank: #125,485 in Books (See Top 100 in Books)
- #11 in Business Research & Development
- #21 in Pharmaceutical & Biotechnology Industry (Books)
- #53 in Vaccinations
- Customer Reviews:
About the author

PETER LOFTUS is a reporter for the Wall Street Journal, covering the drug and medical-device industries and other health care topics. He was part of a Journal team that won second place in the business category of the 2020 Association of Health Care Journalists’ awards for coverage of the race for a Covid-19 vaccine. In 2016 he was part of a Journal team that was a finalist for the Pulitzer Prize in explanatory reporting for a series of articles about rising prescription drug prices. Before joining the Journal in 2013, he was a reporter for Dow Jones Newswires, covering the pharmaceutical and technology industries. Before that, he worked for community newspapers in suburban Philadelphia. He graduated from the University of Notre Dame with a bachelor’s degree in English and history. He lives outside Philadelphia with his wife and three children.
Customer reviews
Customer Reviews, including Product Star Ratings help customers to learn more about the product and decide whether it is the right product for them.
To calculate the overall star rating and percentage breakdown by star, we don’t use a simple average. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. It also analyzed reviews to verify trustworthiness.
Learn more how customers reviews work on Amazon-
Top reviews
Top reviews from the United States
There was a problem filtering reviews right now. Please try again later.
I enjoyed the way Loftus let’s the reader get to know the players involved in Moderna with enough detail and history to become familiar with Moderna’s culture and big goals. I was rooting for them from the start. He takes a lengthy sidebar to explain the science behind the messenger RNA vaccine. It bogged me down for a bit, but ultimately it was extremely helpful in understanding the science and how bits and pieces from various patents and research partners came together.
On a broader note, this is an important piece of history to have summarized and documented. The quest for a vaccine was such an important moment in our country’s history and this book summarizes how Moderna contributed to the mission. Moderna’s solid basis in messenger RNA science put the company in the right place at the right time. Loftus does a great job unfolding the story of Moderna within the story of the quest for a vaccine. Honestly, although the pandemic was just a few years ago, I had forgotten (maybe purposely?) what a dark, scary time it was and how desperately we were all waiting for a vaccine. Loftus creates that feeling again as he describes all the events involved in tests and manufacturing the first vaccine.
Top reviews from other countries
I ever purchased. Not recommended.
It reads like Bancel’s diary.
Explicates the Pharma push
to get maximum return on
minimum investment,







